Is Rituximab an immunotherapy or a targeted therapy?

Rituximab (Rituximab) is a targeted cancer drug targeting the CD20 molecule on the surface of pre-B cells and mature B lymphocytes. Monoclonal antibodies target proteins on the surface of cancer cells. Rituximab targets a protein called CD20. CD20 is found in white blood cells called B cells. Rituximab works by attaching itself to any CD20 protein it finds. Indicated for the treatment of non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), granulomatosis with polyangiitis (GPA) (Wegener's granulomatosis) and microscopic polyangiitis (MPA), pemphigus vulgaris (PV), and rheumatoid arthritis (RA).